Kamada Ltd. (KMDA)
USD 5.76
(-1.37%)
USD 5.76
(-1.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 21.53 Million USD | 128.94% |
| 2022 | 4.53 Million USD | 101.84% |
| 2021 | 5.19 Million USD | -79.3% |
| 2020 | 25.41 Million USD | -11.56% |
| 2019 | 27.3 Million USD | 19.62% |
| 2018 | 23.46 Million USD | 107.4% |
| 2017 | 11.24 Million USD | 858.9% |
| 2016 | -1.98 Million USD | 80.46% |
| 2015 | -7.09 Million USD | -18.95% |
| 2014 | -8.31 Million USD | -193.02% |
| 2013 | 8.08 Million USD | -11.05% |
| 2012 | 7.18 Million USD | 148.98% |
| 2011 | 2.71 Million USD | 139.67% |
| 2010 | -9.38 Million USD | 39.63% |
| 2009 | -15.51 Million USD | 10.19% |
| 2008 | -14.67 Million USD | -17.02% |
| 2007 | -20.32 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 8.74 Million USD | 53.37% |
| 2024 Q1 | 7.21 Million USD | -8.18% |
| 2023 Q4 | 6.29 Million USD | -0.44% |
| 2023 FY | - USD | 128.94% |
| 2023 Q2 | 5.52 Million USD | 229.71% |
| 2023 Q3 | 6.32 Million USD | 14.48% |
| 2023 Q1 | 1.67 Million USD | -75.16% |
| 2022 Q4 | 6.74 Million USD | 87.57% |
| 2022 Q3 | 3.59 Million USD | 427.89% |
| 2022 FY | - USD | 101.84% |
| 2022 Q1 | 1.26 Million USD | 198.29% |
| 2022 Q2 | -1.09 Million USD | -186.72% |
| 2021 Q4 | -1.28 Million USD | -355.36% |
| 2021 Q2 | 2.37 Million USD | -34.55% |
| 2021 Q3 | 504 Thousand USD | -78.73% |
| 2021 FY | - USD | -79.3% |
| 2021 Q1 | 3.62 Million USD | -11.16% |
| 2020 Q4 | 4.07 Million USD | -56.01% |
| 2020 Q2 | 5.46 Million USD | -14.12% |
| 2020 Q1 | 6.35 Million USD | -7.63% |
| 2020 Q3 | 9.26 Million USD | 69.66% |
| 2020 FY | - USD | -11.56% |
| 2019 FY | - USD | 19.62% |
| 2019 Q3 | 7.15 Million USD | -8.11% |
| 2019 Q4 | 6.88 Million USD | -3.76% |
| 2019 Q2 | 7.78 Million USD | 17.65% |
| 2019 Q1 | 6.61 Million USD | -59.82% |
| 2018 Q1 | 2.41 Million USD | -68.08% |
| 2018 Q4 | 16.46 Million USD | 1246.59% |
| 2018 Q3 | -1.43 Million USD | -122.64% |
| 2018 FY | - USD | 107.4% |
| 2018 Q2 | 6.34 Million USD | 163.04% |
| 2017 Q3 | 681 Thousand USD | -88.61% |
| 2017 FY | - USD | 858.9% |
| 2017 Q4 | 7.55 Million USD | 1009.25% |
| 2017 Q2 | 5.98 Million USD | 317.57% |
| 2017 Q1 | -2.74 Million USD | -191.52% |
| 2016 FY | - USD | 80.46% |
| 2016 Q1 | -982 Thousand USD | -158.38% |
| 2016 Q2 | 421 Thousand USD | 142.87% |
| 2016 Q3 | -7000.00 USD | -101.66% |
| 2016 Q4 | -943 Thousand USD | -13371.43% |
| 2015 Q2 | -1.53 Million USD | 67.96% |
| 2015 Q4 | 1.68 Million USD | 154.57% |
| 2015 Q3 | -3.08 Million USD | -100.52% |
| 2015 Q1 | -4.79 Million USD | -236.63% |
| 2015 FY | - USD | -18.95% |
| 2014 Q3 | -1.33 Million USD | 81.13% |
| 2014 Q1 | -1.8 Million USD | -156.71% |
| 2014 FY | - USD | -193.02% |
| 2014 Q2 | -7.05 Million USD | -291.95% |
| 2014 Q4 | 3.51 Million USD | 363.59% |
| 2013 Q3 | 1.79 Million USD | -26.0% |
| 2013 Q2 | 2.41 Million USD | 712.41% |
| 2013 FY | - USD | -11.05% |
| 2013 Q4 | 3.17 Million USD | 77.43% |
| 2013 Q1 | -395 Thousand USD | -108.86% |
| 2012 Q4 | 4.45 Million USD | 97.04% |
| 2012 FY | - USD | 148.98% |
| 2012 Q2 | -135 Thousand USD | 0.0% |
| 2012 Q3 | 2.26 Million USD | 1776.3% |
| 2011 FY | - USD | 139.67% |
| 2010 FY | - USD | 39.63% |
| 2009 FY | - USD | 10.19% |
| 2008 FY | - USD | -17.02% |
| 2007 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Journey Medical Corporation | 1.92 Million USD | -1020.979% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 80.302% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -1721.827% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 86.781% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 663.066% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 663.066% |
| SCYNEXIS, Inc. | 73.47 Million USD | 70.694% |
| Safety Shot Inc | -12.18 Million USD | 276.723% |
| Alpha Teknova, Inc. | -25.53 Million USD | 184.318% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 93.016% |
| Bright Green Corporation | - USD | -Infinity% |
| Dynavax Technologies Corporation | 9.66 Million USD | -122.781% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 114.346% |
| Cosmos Health Inc. | -17.06 Million USD | 226.212% |
| PainReform Ltd. | -9.56 Million USD | 325.039% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 1015.947% |
| Embecta Corp. | 245.4 Million USD | 91.225% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 113.556% |
| Procaps Group, S.A. | 104.02 Million USD | 79.3% |
| Theratechnologies Inc. | -10.31 Million USD | 308.809% |
| Harrow Health, Inc. | 9.72 Million USD | -121.475% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 575.89% |
| Biofrontera Inc. | -18.45 Million USD | 216.696% |
| DURECT Corporation | -24.68 Million USD | 187.239% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 78.085% |
| Cronos Group Inc. | -72.14 Million USD | 129.847% |
| OptiNose, Inc. | -15.55 Million USD | 238.456% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 102.328% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 159.681% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 18.016% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 40.235% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 649.007% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 3129.331% |
| Radius Health, Inc. | 38.31 Million USD | 43.79% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 769.783% |
| ProPhase Labs, Inc. | -14.82 Million USD | 245.235% |
| Phibro Animal Health Corporation | 84.6 Million USD | 74.548% |
| Procaps Group S.A. | 104.02 Million USD | 79.3% |
| Alvotech | -484.86 Million USD | 104.441% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 356.327% |
| Viatris Inc. | 3.51 Billion USD | 99.388% |
| Rockwell Medical, Inc. | -4.69 Million USD | 558.756% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 2227.866% |
| SIGA Technologies, Inc. | 84.15 Million USD | 74.413% |
| Tilray Brands, Inc. | -72.84 Million USD | 129.562% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -2551.97% |
| Shineco, Inc. | -26.55 Million USD | 181.095% |
| PetIQ, Inc. | 81.48 Million USD | 73.573% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 695.252% |
| Incannex Healthcare Limited | -18.5 Million USD | 216.375% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 94.825% |
| Alimera Sciences, Inc. | 7.27 Million USD | -195.959% |
| Silver Spike Investment Corp. | 7.34 Million USD | -193.374% |
| Assertio Holdings, Inc. | -222.44 Million USD | 109.681% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 639.611% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 611.269% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 228.148% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 207.505% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 114.44% |
| Hempacco Co., Inc. | -12.77 Million USD | 268.586% |
| Talphera, Inc. | -9.84 Million USD | 318.797% |
| Alvotech | -484.86 Million USD | 104.441% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 72.215% |
| Lantheus Holdings, Inc. | 491 Million USD | 95.614% |
| Currenc Group, Inc. | -1.9 Million USD | 1233.026% |
| Indivior PLC | 66 Million USD | 67.373% |
| Evoke Pharma, Inc. | -7.29 Million USD | 395.298% |
| Flora Growth Corp. | -45.87 Million USD | 146.946% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 207.505% |
| Evolus, Inc. | -41.81 Million USD | 151.504% |
| HUTCHMED (China) Limited | 25.52 Million USD | 15.646% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 91.082% |
| Akanda Corp. | -27.73 Million USD | 177.64% |